Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2results about How to "Weak side effects" patented technology

Yoghourt for assisting in reducing uric acid and preparation method thereof

The invention discloses yoghourt capable of assisting in reducing uric acid and a preparation method of the yoghourt. The yoghourt is prepared from the following raw materials: 700-900 parts of skim milk, 150-200 parts of pomegranate juice, 50-80 parts of erythritol, 10-50 parts of modified starch, 10-20 parts of bean flour and 10-20 parts of whey protein powder, and the dosage of a leavening agent in every 1000 kg of the raw materials is 50-200 U. All the selected components have a certain uric acid reducing effect and have a synergistic effect, and the whey protein powder and the modified starch are beneficial for improving competitive nucleoside absorption of probiotics and intestinal epithelial cells and reducing purine absorption; polyphenol in the pomegranate juice and ketone substances in the bean flour synergistically improve the oxidation resistance of polar substances, inhibit the activity of xanthine oxidase and reduce the synthesis of uric acid in the body; the bean flour, the pomegranate juice, the whey protein powder and the modified starch are beneficial to promoting the probiotics to repair intestinal barriers and relieve inflammation, so that the expression of uric acid transporter protein is facilitated, the discharge of uric acid is accelerated, and the effect of the probiotic flavored fermented milk on the aspect of reducing uric acid is comprehensively improved.
Owner:YANGZHOU YANGDA KANGYUAN DAIRY

A peptide targeting cGAS and its applications

This invention belongs to the field of biomedical technology and relates to a polypeptide targeting cGAS and its applications. The polypeptide comprises an active peptide and a membrane-penetrating peptide, the membrane-penetrating peptide being fused to the N-terminus of the active peptide. The amino acid sequence of the active peptide is identical to amino acid regions 45-63 of human IκB kinase-binding protein (IKIP) or 43-60 of mouse IKIP. The polypeptide provided by this invention can enter cells, specifically bind to cGAS, inhibit cGAS aggregation and phase separation, thereby inhibiting cGAS enzyme activity, reducing type I interferon expression, maintaining antiviral immune homeostasis, and providing a new candidate strategy for the clinical treatment of viral infections and autoimmune diseases.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)